<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1802">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05137704</url>
  </required_header>
  <id_info>
    <org_study_id>TAK-489-4005</org_study_id>
    <nct_id>NCT05137704</nct_id>
  </id_info>
  <brief_title>A Study on the Use of Healthcare Resources and Costs of Attention Deficit Hyperactivity Disorder (ADHD) in Adults in England</brief_title>
  <official_title>Healthcare Resources Utilization and Associated Costs of Adult ADHD in England</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main aim of the study is to learn about the demographic and clinical characteristics,&#xD;
      healthcare resources utilization (HCRU) and costs associated with before and after ADHD&#xD;
      diagnosis in England. No study medicines will be provided to participants in this study. The&#xD;
      record available in Clinical Practice Research Datalink (CPRD) database and Hospital Episode&#xD;
      Statistics (HES) database for ADHD participants will be assessed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of General Practitioner (GP) Appointments</measure>
    <time_frame>Up to approximately 36 months</time_frame>
    <description>Number of GP appointments will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Referrals to Psychiatrist</measure>
    <time_frame>Up to approximately 36 months</time_frame>
    <description>Number of referrals to psychiatrist will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Referrals by Specialist</measure>
    <time_frame>Up to approximately 36 months</time_frame>
    <description>Number of referrals by specialist will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Outpatient Visits by Specialist</measure>
    <time_frame>Up to approximately 36 months</time_frame>
    <description>Number of outpatient visits by specialist will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Investigations Undergone</measure>
    <time_frame>Up to approximately 36 months</time_frame>
    <description>Number and type of investigations undergone will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Accident and Emergency Visits</measure>
    <time_frame>Up to approximately 36 months</time_frame>
    <description>Number of accident and emergency visits will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Reasons for Admission</measure>
    <time_frame>Up to approximately 36 months</time_frame>
    <description>Number of reasons for admission will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Inpatient Hospitalizations</measure>
    <time_frame>Up to approximately 36 months</time_frame>
    <description>Number of inpatient hospitalizations will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Length of Stay in Hospital</measure>
    <time_frame>Up to approximately 36 months</time_frame>
    <description>Length of stay in hospital will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Healthcare Costs</measure>
    <time_frame>Up to approximately 36 months</time_frame>
    <description>Health care cost includes prescription costs, primary health care consultations, investigations, hospital admissions, and outpatient appointments.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Prescribed With Pharmacological Treatments</measure>
    <time_frame>Up to approximately 36 months</time_frame>
    <description>Number of participants prescribed with pharmacological treatment will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Received Non-Pharmacological Treatments</measure>
    <time_frame>Up to approximately 36 months</time_frame>
    <description>The number of participants who received non-pharmacological treatments will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Received Non-Pharmacological Therapy</measure>
    <time_frame>Up to approximately 36 months</time_frame>
    <description>The non-pharmacological therapy will be cognitive behavioural therapy. Number of participants who received non-pharmacological therapy will be reported.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">11412</enrollment>
  <condition>Attention Deficit Hyperactivity Disorder (ADHD)</condition>
  <arm_group>
    <arm_group_label>Participant With ADHD</arm_group_label>
    <description>The record available for ADHD participants in primary care-based electronic medical records in the CPRD database linked to secondary care based episodic claims data available in HES database will be assessed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>This is a non-interventional study.</description>
    <arm_group_label>Participant With ADHD</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participant diagnosed with ADHD recorded between 01 January 2016 and 30 June 2018.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Age greater than or equal to (&gt;=) 18 years at the beginning of the patient observation&#xD;
             period (that is 18-months prior to the adult ADHD diagnosis to ensure they would have&#xD;
             been seen in adult health care services).&#xD;
&#xD;
          2. First record of an adult ADHD diagnosis between 01st January 2016 and 30th June 2018.&#xD;
&#xD;
          3. Data availability in the database at least during the 18-months before and after the&#xD;
             index date.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        A participant will be excluded from the study if their CPRD linked to HES electronic&#xD;
        medical record data includes:&#xD;
&#xD;
          1. Incomplete information for key demographics (that is, missing age or sex).&#xD;
&#xD;
          2. Clinical history of a diagnosis of ADHD during childhood or adolescence.&#xD;
&#xD;
          3. Prescription of a licensed adult ADHD medication (that is, methylphenidate,&#xD;
             lisdexamfetamine, dexamfetamine, atomoxetine) during the pre-index period.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Takeda Contact</last_name>
    <phone>+1-877-825-3327</phone>
    <email>medinfoUS@takeda.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>IQVIA Ltd</name>
      <address>
        <city>London</city>
        <zip>N19JY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <email>Marios.Adamou@swyt.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Marios Adamou, MD. PhD. OBE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://clinicaltrials.takeda.com/study-detail/61a6927bf571d4002a64b43a</url>
    <description>To obtain more information on the study, click here/on this link</description>
  </link>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>November 25, 2021</study_first_submitted>
  <study_first_submitted_qc>November 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 30, 2021</study_first_posted>
  <last_update_submitted>December 2, 2021</last_update_submitted>
  <last_update_submitted_qc>December 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperkinesis</mesh_term>
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_access_criteria>IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/ For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/takeda/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

